Eli Lilly Says Its Obesity Pill Topped Novo Nordisk's Oral Drug In Late-Stage Diabetes Trial
(MENAFN- AsiaNet News)
Eli Lilly and Company (LLY) stated on Wednesday that its oral weight-loss drug was found to be superior to its rival Novo Nordisk's (NVO) oral Semaglutide in a head-to-head late-stage trial.
The study evaluated the safety and efficacy of Lilly's Orforglipron in 1,698 adults with type 2 diabetes as compared to oral Semaglutide. At 52 weeks, Orforglipron met the primary and all key secondary endpoints across each dose comparison as compared to oral Semaglutide, delivering greater improvements in average blood sugar levels and weight, the company said.
Get updates to this developing story <directly on Stocktwits.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Chicago Clearing Corporation And Taxtec Announce Strategic Partnership
- Everstake Expands Institutional Solana Services With Shredstream, Swqos, And Validator-As-A-Service
- Japan Smart Cities Market Size Is Expected To Reach USD 286.6 Billion By 2033 CAGR: 14.6%
- Alchemy Markets Launches Tradingview Integration For Direct Chart-Based Trading
- Blackrock Becomes The Second-Largest Shareholder Of Freedom Holding Corp.
- Pluscapital Advisor Empowers Traders To Master Global Markets Around The Clock
More Story
Comments
No comment